Molecular targets and early response biomarkers for the prediction of developmental toxicity in vitro

Alternatives to Laboratory Animals

Volumn 35, Issue 3, 2007, Pages 335-342

  Stigson, Michael ^a   Kultima, Kim ^a   Jergil, Måns ^a   Scholz, Birger ^a   Alm, Henrik ^a   Gustafson, Anne Lee ^b   Dencker, Lennart ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Embryo; Microarray; Neural tube defect; P19 mouse embryocarcinoma cells; Valproic acid

Indexed keywords

BIOLOGICAL MARKER; VALPROIC ACID;

CARCINOMA CELL; CONFERENCE PAPER; DRUG INTOXICATION; EMBRYOTOXICITY; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; NEURAL TUBE DEFECT; NONHUMAN; PREDICTION; PRIORITY JOURNAL; TERATOGENICITY; TOXICOGENETICS;

ANIMALIA;

EID: 34547726788     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119290703500313     Document Type: Conference Paper

References (48)

1. Chapin, R., Stedman, D., Paquette, J., Streck, R., Kumpf, S. & Deng, S. (2006). Struggles for equivalence: In vitro developmental toxicity model evolution in pharmaceuticals in 2006. Toxicology in Vitro doi:10.1016/j.tiv.2006.10.006 (Accessed 10.05.07).
2. Frank, R. & Hargreaves, R. (2003). Clinical biomarkers in drug discovery and development. Nature Reviews Drug Discovery 2, 566-580.
3. Kola, I. & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 3, 711-715.
4. Genschow, E., Spielmann, H., Scholz, G., Pohl, I., Seiler, A., Clemann, N., Bremer, S. & Becker, K. (2004). Validation of the embryonic stem cell test in the international ECVAM validation study on three in vitro embryotoxicity tests. ATLA 32, 209-244.
5. Genschow, E., Spielmann, H., Scholz, G., Seiler, A., Brown, N., Piersma, A., Brady, M., Clemann, N., Huuskonen, H., Paillard, F., Bremer, S. & Becker, K. (2002). The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. ATLA 30, 151-176.
6. Piersma, A.H., Genschow, E., Verhoef, A., Spanjersberg, M.Q., Brown, N.A., Brady, M., Burns, A., Clemann, N., Seiler, A. & Spielmann, H. (2004). Validation of the postimplantation rat whole-embryo culture test in the international ECVAM validation study on three in vitro embryotoxicity tests. ATLA 32, 275-307.
7. Spielmann, H., Genschow, E., Brown, N.A., Piersma, A.H., Verhoef, A., Spanjersberg, M.Q., Huuskonen, H., Paillard, F. & Seiler, A. (2004). Validation of the rat limb bud micromass test in the international ECVAM validation study on three in vitro embryotoxicity tests. ATLA 32, 245-274.
8. Spielmann, H., Seiler, A., Bremer, S., Hareng, L., Hartung, T., Ahr, H., Faustman, E., Haas, U., Moffat, G.J., Nau, H., Vanparys, P., Piersma, A., Sintes, J.R. & Stuart, J. (2006). The practical application of three validated in vitro embryotoxicity tests. The report and recommendations of an ECVAM/ZEBET workshop (ECVAM workshop 57). ATLA 34, 527-538.
9. ECVAM (2002). Embryotoxicity Testing in Post-Implantation Embryo Culture - Method of Piersma. INVITTOX Protocol No. 123 Web site: http://ecvam-dbalm.jrc. cec.eu.int/public_view_doc.cfm?id= 15BFE9AC6ECC8ED3D7F6DF03B5D5BBE97180BB0BC12CB10496CDA74B54630A05A3291B895581 F63 4 (Accessed 10.05.07).
10. ECVAM (2002). The Micromass Test - Method of Brown. INVITTOX Protocol No. 122 Web site: http://ecvam-dbalm.jrc.cec.eu.int/public_view_doc.cfm?id= 7DDBC8A6A03A1DB626729D0A17A0D2FF7180BB0BC12CB10496CDA74B54630A05A3291B895581 F63 4 (Accessed 10.05.07).
11. ECVAM (2002). Embryonic Stem Cell Test (EST). INVITTOX Protocol No. 113 Web site: http://ecvam-dbalm.jrc.cec.eu.int/public_view_doc.cfm?id= DC5ABDF7AC30F1B7DF7EF27E87D68AAC7180BB0BC12CB10496CDA74B54630A05A3291B895581 F63 4 (Accessed 10.05.07).
12. Seiler, A.E., Buesen, R., Visan, A. & Spielmann, H. (2006). Use of murine embryonic stem cells in embryo-toxicity assays: the embryonic stem cell test. Methods in Molecular Biology 329, 371-395.
13. Russell, W.M.S. & Burch, R.L. (1959). The Principles of Humane Experimental Technique, 238pp. London, UK: Methuen.
14. Genschow, E., Scholz, G., Brown, N., Piersma, A., Brady, M., Clemann, N., Huuskonen, H., Paillard, F., Bremer, S., Becker, K. & Spielmann, H. (2000). Development of prediction models for three in vitro embryotoxicity tests in an ECVAM validation study. In Vitro and Molecular Toxicology 13, 51-66.
15. McNeish, J. (2004). Embryonic stem cells in drug discovery. Nature Reviews Drug Discovery 3, 70-80.
16. Seiler, A., Visan, A., Buesen, R., Genschow, E. & Spielmann, H. (2004). Improvement of an in vitro stem cell assay for developmental toxicity: the use of molecular endpoints in the embryonic stem cell test. Reproductive Toxicology 18, 231-240.
17. Wilson, J.G. (1959). Experimental studies on congenital malformations. Journal of Chronic Diseases 10, 111-130.
18. Wilson, J.G. (1973). Environment and Birth Defects, 305pp. New York, NY, USA: Academic Press.
19. Eikel, D., Lampen, A. & Nau, H. (2006). Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chemical Research in Toxicology 19, 272-278.
20. Menegola, E., Di Renzo, F., Broccia, M.L., Prudenziati, M., Minucci, S., Massa, V. & Giavini, E. (2005). Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. Birth Defects Research Part B: Developmental and Reproductive Toxicology 74, 392-398.
21. Svensson, K., Mattsson, R., James, T.C., Wentzel, P., Pilartz, M., MacLaughlin, J., Miller, S.J., Olsson, T., Eriksson, U.J. & Ohlsson, R. (1998). The paternal allele of the H19 gene is progressively silenced during early mouse development: the acetylation status of histones may be involved in the generation of variegated expression patterns. Development 125, 61-69.
22. Göttlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., Sleeman, J.P., Lo Coco, F., Nervi, C., Pelicci, P.G. & Heinzel, T. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO Journal 20, 6969-6978.
23. Glaser, K.B., Staver, M.J., Waring, J.F., Stender, J., Ulrich, R.G. & Davidsen, S.K. (2003). Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Molecular Cancer Therapeutics 2, 151-163.
24. Johnstone, R.W. (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Reviews Drug Discovery 1, 287-299.
25. Johnstone, R.W. & Licht, J.D. (2003). Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13-18.
26. Marks, P.A., Miller, T. & Richon, V.M. (2003). Histone deacetylases. Current Opinion in Pharmacology 3, 344-351.
27. Zupkovitz, G., Tischler, J., Posch, M., Sadzak, I., Ramsauer, K., Egger, G., Grausenburger, R., Schweifer, N., Chiocca, S., Decker, T. & Seiser, C. (2006). Negative and positive regulation of gene expression by mouse histone deacetylase 1. Molecular and Cellular Biology 26, 7913-7928.
28. Gurvich, N., Herman, M.G., Wittner, B.S., Gentleman, R.C., Klein, P.S. & Green, J.B. (2005). Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB Journal 191, 166-168.
29. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Richon, V.M., Marks, P.A. & Anderson, K.C. (2004). Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proceedings of the National Academy of Sciences of the USA 101, 540-545.
30. Wise, L.D., Turner, K.J. & Kerr, J.S. (2007). Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Birth Defects Research, Part B: Developmental and Reproductive Toxicology 80, 57-68.
31. Kultima, K., Nystrom, A.M., Scholz, B., Gustafson, A.L., Dencker, L. & Stigson, M. (2004). Valproic acid teratogenicity: a toxicogenomics approach. Environmental Health Perspectives 112, 1225-1235.
32. Nau, H. & Löscher, W. (1986). Pharmacologie evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundamental and Applied Toxicology 6, 669-676.
33. Copp, A.J., Greene, N.D. & Murdoch, J.N. (2003). The genetic basis of mammalian neurulation. Nature Reviews Genetics 4, 784-793.
34. Harris, M.J. & Juriloff, D.M. (2007). Mouse mutants with neural tube closure defects and their role in understanding human neural tube defects. Birth Defects Research Part A: Clinical and Molecular Teratology 79, 187-210.
35. Copp, A., Brook, F.A., Estibeiro, J.P., Shum, A.S. & Cockroft, D.L. (1990). The embryonic development of mammalian neural tube defects. Progress in Neurobiology 35, 363-403.
36. Phiel, C.J., Zhang, F., Huang, E.Y., Guenther, M.G., Lazar, M.A. & Klein, P.S. (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry 276, 36,734-36,741.
37. Blaheta, R.A. & Cinatl, J., Jr. (2002). Anti-tumor mechanisms of valproate: a novel role for an old drug. Medicinal Research Reviews 22, 492-511.
38. Blaheta, R.A., Michaelis, M., Driever, P.H. & Cinatl, J., Jr. (2005). Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies. Medicinal Research Reviews 25, 383-397.
39. Marks, P., Rifkind, R.A., Richon, V.M., Breslow, R., Miller, T. & Kelly, W.K. (2001). Histone deacetylases and cancer: causes and therapies. Nature Reviews Cancer 1, 194-202.
40. Boiani, M. & Scholer, H.R. (2005). Regulatory networks in embryo-derived pluripotent stem cells. Nature Reviews Molecular Cell Biology 6, 872-884.
41. Adler, S., Paparella, M., Pellizzer, C., Hartung, T. & Bremer, S. (2005). The detection of differentiation-inducing chemicals by using green fluorescent protein expression in genetically engineered terato-carcinoma cells. ATLA 33, 91-103.
42. Werling, U., Siehler, S., Litfin, M., Nau, H. & Gottlicher, M. (2001). Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivatives. Molecular Pharmacology 59, 1269-1276.
43. Kultima, K., Jergil, M., Scholz, B., Gustafson, A-L., Dencker, L. & Stigson, M. (2007). In search for molecular markers of teratogenicity using a toxicogenomics in vivo/in vitro approach. Paper II, in Transcriptomics and Proteomics Applied to Developmental Toxicology (K. Kultima, PhD Thesis). Uppsala, Sweden: University of Uppsala.
44. Winograd, J., Reilly, M.P., Roe, R., Lutz, J., Laughner, E., Xu, X., Hu, L., Asakura, T., van der Kolk, C., Strandberg, J.D. & Semenza, G.L. (1997). Perinatal lethality and multiple craniofacial malformations in MSX2 transgenic mice. Human Molecular Genetics 6, 369-379.
45. Adler, S., Pellizzer, C., Paparella, M., Hartung, T. & Bremer, S. (2006). The effects of solvents on embryonic stem cell differentiation. Toxicology in Vitro 20, 265-271.
46. Singh, A.V., Knudsen, K.B. & Knudsen, T.B. (2005). Computational systems analysis of developmental toxicity: design, development and implementation of a Birth Defects Systems Manager (BDSM). Reproductive Toxicology 19, 421-439.
47. Ying, Q.L., Stavridis, M., Griffiths, D., Li, M. & Smith, A. (2003). Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. Nature Biotechnology 21, 183-186.
48. Seiler, A., Buesen, R., Hayess, K., Schlechter, K., Visan, A., Genschow, E., Slawik, B. & Spielmann, H. (2006). Current status of the embryonic stem cell test: The use of recent advances in the field of stem cell technology and gene expression analysis. ALTEX 23, 393-399.